Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This treatment study is targeted specifically for those who want to stop using marijuana. We
want to find out if patients who are dependent on marijuana and want to stop using are helped
by a combination of the drug dronabinol and six sessions of individual therapy (BRENDA).
Dronabinol is a pill form of the active ingredient in marijuana (THC). Currently, dronabinol
is approved for the treatment of nausea in people receiving cancer chemotherapy and as an
appetite stimulant in people with AIDS.
In some studies, dronabinol reduced the amount of psychological and physical discomfort
experienced when people stopped using marijuana. One purpose of our study is to see if people
who are on dronabinol have fewer problems with psychological and physical discomfort than
those who are on a placebo.
In addition to treatment, this research trial will also be measuring the reactions of
subjects to drug-related cues, and also to computer-presented tasks unrelated to drug use. We
may examine whether the response to these cues/tasks either predicts treatment outcome, or is
affected by your treatment. This information may also help us to understand the ways in which
chronic drug use causes changes in our subjects' mental functioning and how those changes
respond to treatment.
In addition to participation in the treatment research trial, some subjects may be asked to
undergo a brain scan in an MRI. The purpose of the brain scan research project is to measure
brain reactions with a non-invasive, non-radioactive imaging technique known as fMRI
(functional magnetic resonance imaging) in marijuana subjects before and after treatment with
the medication dronabinol or with an inactive substance (placebo).